

WEST Search History

DATE: Thursday, December 15, 2005

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L51	L50 not @ay>2002	240
<input type="checkbox"/>	L50	L49 and polymer	319
<input type="checkbox"/>	L49	L48 and l11	346
<input type="checkbox"/>	L48	l45 and l3	486
<input type="checkbox"/>	L47	L45 and l1	2
<input type="checkbox"/>	L46	L45 an dl1	0
<input type="checkbox"/>	L45	L44 or l43 or l42	40636
<input type="checkbox"/>	L44	(424/484,486,489,490,491)![CCLS]	7451
<input type="checkbox"/>	L43	(514/962,963)![CCLS]	768
<input type="checkbox"/>	L42	(435/6)![CCLS]	32631
<input type="checkbox"/>	L41	L40 and L9	18
<input type="checkbox"/>	L40	L36 not L39	18
<input type="checkbox"/>	L39	L36 not L37	109
<input type="checkbox"/>	L38	L37 not L36	321
<input type="checkbox"/>	L37	L29 or L28	339
<input type="checkbox"/>	L36	L35 not @ay>2001	127
<input type="checkbox"/>	L35	L34 and L9	357
<input type="checkbox"/>	L34	L33 and L11	439
<input type="checkbox"/>	L33	L32 and L2	612
<input type="checkbox"/>	L32	L31 and L7	649
<input type="checkbox"/>	L31	L30 or L29 or L28	1450
<input type="checkbox"/>	L30	L27.clm.	1277
<input type="checkbox"/>	L29	L27.ab.	321
<input type="checkbox"/>	L28	L27.ti.	158
<input type="checkbox"/>	L27	L26 or L19	10018
<input type="checkbox"/>	L26	interleukin NEAR2 12	3192
<input type="checkbox"/>	L25	L24 not @ay>2002	16
<input type="checkbox"/>	L24	L23 and L9	34
<input type="checkbox"/>	L23	L22 and L2	36
<input type="checkbox"/>	L22	L21 and L11	39
<input type="checkbox"/>	L21	L20 and L7	53

<input type="checkbox"/>	L20	L19.ab.	245
<input type="checkbox"/>	L19	IL NEAR2 12	8831
<input type="checkbox"/>	L18	L17 not @py>2001	8
<input type="checkbox"/>	L17	L16 and L9	48
<input type="checkbox"/>	L16	L7 and L15	57
<input type="checkbox"/>	L15	L14 and L3	103
<input type="checkbox"/>	L14	L11.ab.	31903
<input type="checkbox"/>	L13	L3 and L6	3154
<input type="checkbox"/>	L12	L10 and L11	2
<input type="checkbox"/>	L11	liposom\$ or microspher\$ or encapsula\$	249505
<input type="checkbox"/>	L10	L8 and L9	5
<input type="checkbox"/>	L9	oral\$	197396
<input type="checkbox"/>	L8	L7 and L5	5
<input type="checkbox"/>	L7	gastrointestin\$ or esophag\$ or gastic? or intestin\$ or colorectal\$	116454
<input type="checkbox"/>	L6	gastrointestin\$ or esophag\$ or gastic? or intestin? or colorectal?	86265
<input type="checkbox"/>	L5	L2 and L4	8
<input type="checkbox"/>	L4	L3.ab.	25
<input type="checkbox"/>	L3	sulindac	4836
<input type="checkbox"/>	L2	cancer\$ or tumor\$ or neoplas\$	179146
<input type="checkbox"/>	L1	egilmez.in.	6

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:21:20 ON 15 DEC 2005

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.21

0.21

FILE 'PCTFULL' ENTERED AT 08:21:30 ON 15 DEC 2005

COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 13 DEC 2005 <20051213/UP>

MOST RECENT UPDATE WEEK: 200549 <200549/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> KWIC format free of charge - SEE NEWS >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html <

=> s microspher?

L1 15203 MICROSPHER?

=> s l1/ti

L2 343 (MICROSPHER?/TI)

=> s l1/ab

L3 990 (MICROSPHER?/AB)

=> s l2 or l3

L4 1026 L2 OR L3

=> s polyanhydride

1149 POLYANHYDRIDE

5384 POLYANHYDRIDES

L5 6164 POLYANHYDRIDE

(POLYANHYDRIDE OR POLYANHYDRIDES)

=> s sulindac

L6 2826 SULINDAC

=> s l6 and l4

L7 16 L6 AND L4

=> s l7 and l5

L8 3 L7 AND L5

=> d ibib 1-3

L8 ANSWER 1 OF 3

ACCESSION NUMBER:

TITLE (ENGLISH):

TITLE (FRENCH):

INVENTOR(S):

PCTFULL COPYRIGHT 2005 Univentio on STN

2005081825 PCTFULL ED 20050914 EW 200536

ABUSE RESISTANT OPIOID TRANSDERMAL DELIVERY DEVICE

CONTAINING OPIOID ANTAGONIST **MICROSPHERES**

DISPOSITIF DE DISTRIBUTION TRANSDERMIQUE D'OPIOIDES

EMPECHANT UNE UTILISATION ABUSIVE ET CONTENANT DES

MICROSPHERES D'ANTAGONISTES D'OPIOIDES

REIDENBERG, Bruce, 1 Stonycrest Road, Rye, NY 01580, US
[US, US];

SHEVCHUK, Ihor, 11 Shelburne Road, Yonkers, NY 10710,
US [US, US];

TAVARES, Lino, 86 South Glen Road, Kinnelon, NJ 07405,
US [US, US];

LONG, Kevin, 3 Hidden Hill Road, Oak Ridge, NJ 07438,
US [US, US];

MASKIEWICZ, Richard, 88 Saunders Lane, Richfield, CT

06877, US [US, US];
 SHAMEEM, Mohammed, 4 Surim Court, Nanuet, NY 10954, US
 [US, US]
 PATENT ASSIGNEE(S): EURO-CELTIQUE S.A., 122, Boulevard de la Petrusse,
 L-2330 Luxembourg, LU [LU, LU], for all designates
 States except US;
 REIDENBERG, Bruce, 1 Stonycrest Road, Rye, NY 01580, US
 [US, US], for US only;
 SHEVCHUK, Ihor, 11 Shelburne Road, Yonkers, NY 10710,
 US [US, US], for US only;
 TAVARES, Lino, 86 South Glen Road, Kinnelon, NJ 07405,
 US [US, US], for US only;
 LONG, Kevin, 3 Hidden Hill Road, Oak Ridge, NJ 07438,
 US [US, US], for US only;
 MASKIEWICZ, Richard, 88 Saunders Lane, Richfield, CT
 06877, US [US, US], for US only;
 SHAMEEM, Mohammed, 4 Surim Court, Nanuet, NY 10954, US
 [US, US], for US only
 AGENT: DAVIDSON, Clifford, M.\$, Davidson, Davidson & Kappel,
 LLC, 485 Seventh Avenue, 14th Floor, New York, NY
 10018\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 2005081825	A2	20050909
DESIGNATED STATES			
W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW		
RW (ARIPO):	BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2005-US4741	A	20050215
PRIORITY INFO.:	US 2004-60/547,196		20040223

L8 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 2004052339 PCTFULL ED 20040630 EW 200426
 TITLE (ENGLISH): PH TRIGGERED TARGETED CONTROLLED RELEASE SYSTEMS
 TITLE (FRENCH): SYSTEMES DE LIBERATION CONTROLEE CIBLEE A DECLENCHEMENT
 FONCTION DU PH
 INVENTOR(S): SHEFER, Adi, 14 Jason Drive, East Brunswick, NJ 08816,
 US;
 SHEFER, Samuel, David, 14 Jason Drive, East Brunswick,
 NJ 08816, US
 PATENT ASSIGNEE(S): SALVONA LLC, 65 Stults Road, Dayton, NJ 08810, US [US,
 US]
 AGENT: DUNN, McKay, Diane\$, Mathews, Collins, Shepherd &
 McKay, P.A., 100 Thanet Circle, Suite 306, Princeton, NJ
 08540\$, US
 LANGUAGE OF FILING: English
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE

DESIGNATED STATES WO 2004052339 A1 20040624

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
 IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
 MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
 SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
 RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
 RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU
 MC NL PT RO SE SI SK TR
 RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2003-US26142 A 20030821
 PRIORITY INFO.: US 2002-10/315,801 20021209

L8 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2005 Univentio on STN
 ACCESSION NUMBER: 1996040090 PCTFULL ED 20020514
 TITLE (ENGLISH): METHOD FOR REDUCING OR PREVENTING POST-SURGICAL
 ADHESION FORMATION USING 5-LIPOXYGENASE INHIBITORS
 TITLE (FRENCH): PROCEDE POUR LA REDUCTION OU LA PREVENTION DE LA
 FORMATION D'ADHERENCES POST-CHIRURGICALES A L'AIDE
 D'INHIBITEURS DE 5-LIPOXYDASE
 INVENTOR(S): RODGERS, Kathleen, Elizabeth;
 diZEREGA, Gere, Stodder
 PATENT ASSIGNEE(S): UNIVERSITY OF SOUTHERN CALIFORNIA
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9640090	A1	19961219

DESIGNATED STATES W: AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL
 PT SE

APPLICATION INFO.: WO 1996-US8216 A 19960531
 PRIORITY INFO.: US 1995-8/473,183 19950607

=> d his

(FILE 'HOME' ENTERED AT 08:21:20 ON 15 DEC 2005)

FILE 'PCTFULL' ENTERED AT 08:21:30 ON 15 DEC 2005

L1 15203 S MICROSPHER?
 L2 343 S L1/TI
 L3 990 S L1/AB
 L4 1026 S L2 OR L3
 L5 6164 S POLYANHYDRIDE
 L6 2826 S SULINDAC
 L7 16 S L6 AND L4
 L8 3 S L7 AND L5

=> s 17 and polymer
 158886 POLYMER
 122941 POLYMERS
 189307 POLYMER
 (POLYMER OR POLYMERS)

L9 16 L7 AND POLYMER

=> s 17 not py>2002
 339965 PY>2002
 L10 12 L7 NOT PY>2002

=> s cancer? or tumor? or cancer?

73935 CANCER?

61948 TUMOR?

73935 CANCER?

L11 90719 CANCER? OR TUMOR? OR CANCER?

=> s l11 and l12

L12 NOT FOUND

The L-number entered could not be found. To see the definition of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l11 and l10

L12 12 L11 AND L10

=> s polymeric

89217 POLYMERIC

178 POLYMERICS

L13 89307 POLYMERIC

(POLYMERIC OR POLYMERICS)

=> s l13 or l9

L14 89310 L13 OR L9

=> s polymer

158886 POLYMER

122941 POLYMERS

L15 189307 POLYMER

(POLYMER OR POLYMERS)

=> s l15 or l13

L16 208045 L15 OR L13

=> s l16 and l7

L17 16 L16 AND L7

=> s l17 not py>2001

443951 PY>2001

L18 11 L17 NOT PY>2001

=> d ibib 1-5

L18 ANSWER 1 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER: 2001072281 PCTFULL ED 20020822

TITLE (ENGLISH): **MICROSPHERES** FOR ACTIVE EMBOLIZATION

TITLE (FRENCH): **MICROSPHERES** PERMETTANT UNE EMBOLISATION ACTIVE

INVENTOR(S): VOGEL, Jean-Marie;

BOSCHETTI, Egisto

PATENT ASSIGNEE(S): BIOSPHERE MEDICAL INC.;

VOGEL, Jean-Marie;

BOSCHETTI, Egisto

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO. 2001072281	A2	20011004
----------------	----	----------

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH

CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US9619 A 20010323
PRIORITY INFO.: US 2000-60/191,899 20000324

L18 ANSWER 2 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001072280 PCTFULL ED 20020822
TITLE (ENGLISH): **MICROSPHERES** FOR GENE THERAPY
TITLE (FRENCH): COMPOSITIONS ET METHODES POUR THERAPIE GENIQUE
INVENTOR(S): VOGEL, Jean-Marie;
BOSCHETTI, Egisto
PATENT ASSIGNEE(S): BIOSPHERE MEDICAL INC.;
VOGEL, Jean-Marie;
BOSCHETTI, Egisto
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001072280	A2	20011004

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US9618 A 20010323
PRIORITY INFO.: US 2000-60/191,902 20000324

L18 ANSWER 3 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001070291 PCTFULL ED 20020822
TITLE (ENGLISH): INJECTABLE **MICROSPHERES** FOR DERMAL
AUGMENTATION AND TISSUE BULKING
TITLE (FRENCH): **MICROSPHERES** INJECTABLES DESTINEES A
L'AUGMENTATION DERMIQUE ET AU GONFLEMENT TISSULAIRE
INVENTOR(S): VOGEL, Jean-Marie;
THOMAS, Richard;
BOSCHETTI, Egisto
PATENT ASSIGNEE(S): BIOSPHERE MEDICAL, INC.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001070291	A2	20010927

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US8529 A 20010315
PRIORITY INFO.: US 2000-09/528,991 20000320

L18 ANSWER 4 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 2001070289 PCTFULL ED 20020822
TITLE (ENGLISH): INJECTABLE AND SWELLABLE **MICROSPHERES** FOR
TISSUE BULKING
TITLE (FRENCH): **MICROSPHERES** INJECTABLES, SUSCEPTIBLES DE

INVENTOR(S): FOISONNEMENT, VISANT A FAIRE GONFLER UN TISSU
VOGEL, Jean-Marie;
PATENT ASSIGNEE(S): BOSCHETTI, Egisto
DOCUMENT TYPE: BIOSPHERE MEDICAL, INC.
PATENT INFORMATION: Patent

NUMBER	KIND	DATE
--------	------	------

WO 2001070289	A2	20010927
---------------	----	----------

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 2001-US8405	A	20010315
----------------	---	----------

PRIORITY INFO.:

US 2000-09/528,989		20000320
--------------------	--	----------

L18 ANSWER 5 OF 11

PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER:

2000024378 PCTFULL ED 20020515

TITLE (ENGLISH):

COMPOSITIONS OF **MICROSPHERES** FOR WOUND
HEALING

TITLE (FRENCH):

COMPOSITIONS A BASE DE **MICROSPHERES** DESTINEES
AU TRAITEMENT DES BLESSURES

INVENTOR(S):

RITTER, Vladimir;
RITTER, Marina

PATENT ASSIGNEE(S):

POLYHEAL LTD;
RITTER, Vladimir;
RITTER, Marina

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 2000024378	A1	20000504
---------------	----	----------

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD
SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:

WO 1998-IB1838	A	19981023
----------------	---	----------

=> d ibib 6-10

L18 ANSWER 6 OF 11

PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER:

1998051284 PCTFULL ED 20020514

TITLE (ENGLISH):

NOVEL ACOUSTICALLY ACTIVE DRUG DELIVERY SYSTEMS

TITLE (FRENCH):

NOUVEAUX SYSTEMES D'ADMINISTRATION DE MEDICAMENTS
ACTIVES PAR UN PROCEDE ACOUSTIQUE

INVENTOR(S):

UNGER, Evan, C.

PATENT ASSIGNEE(S):

IMARX PHARMACEUTICAL CORP.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

	WO 9851284	A1 19981119
DESIGNATED STATES		
W:	AU BR CA CN JP KR NZ AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE	
APPLICATION INFO.:	WO 1998-US9569	A 19980512
PRIORITY INFO.:	US 1997-60/046,379	19970513
	US 1998-9/075,343	19980511
L18 ANSWER 7 OF 11	PCTFULL COPYRIGHT 2005 Univentio on STN	
ACCESSION NUMBER:	1996040090 PCTFULL ED 20020514	
TITLE (ENGLISH):	METHOD FOR REDUCING OR PREVENTING POST-SURGICAL ADHESION FORMATION USING 5-LIPOXYGENASE INHIBITORS	
TITLE (FRENCH):	PROCEDE POUR LA REDUCTION OU LA PREVENTION DE LA FORMATION D'ADHERENCES POST-CHIRURGICALES A L'AIDE D'INHIBITEURS DE 5-LIPOXYDASE	
INVENTOR(S):	RODGERS, Kathleen, Elizabeth; dizEREGA, Gere, Stodder	
PATENT ASSIGNEE(S):	UNIVERSITY OF SOUTHERN CALIFORNIA	
LANGUAGE OF PUBL.:	English	
DOCUMENT TYPE:	Patent	
PATENT INFORMATION:		
	NUMBER	KIND DATE

	WO 9640090	A1 19961219
DESIGNATED STATES		
W:	AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE	
APPLICATION INFO.:	WO 1996-US8216	A 19960531
PRIORITY INFO.:	US 1995-8/473,183	19950607
L18 ANSWER 8 OF 11	PCTFULL COPYRIGHT 2005 Univentio on STN	
ACCESSION NUMBER:	1995015118 PCTFULL ED 20020514	
TITLE (ENGLISH):	GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION	
TITLE (FRENCH):	MICROSPHERES GAZEUSES POUR APPLICATION TOPIQUE ET SOUS-CUTANEE	
INVENTOR(S):	UNGER, Evan, C.; MATSUNAGA, Terry; YELLOWHAIR, David	
PATENT ASSIGNEE(S):	UNGER, Evan, C.; MATSUNAGA, Terry; YELLOWHAIR, David	
LANGUAGE OF PUBL.:	English	
DOCUMENT TYPE:	Patent	
PATENT INFORMATION:		
	NUMBER	KIND DATE

	WO 9515118	A1 19950608
DESIGNATED STATES		
W:	AU CA CN JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE	
APPLICATION INFO.:	WO 1994-US13817	A 19941130
PRIORITY INFO.:	US 1993-8/159,674	19931130
	US 1993-8/159,687	19931130
	US 1993-8/160,232	19931130
	US 1994-8/307,305	19940916
	US 1994-8/346,426	19941129
L18 ANSWER 9 OF 11	PCTFULL COPYRIGHT 2005 Univentio on STN	
ACCESSION NUMBER:	1994028874 PCTFULL ED 20020513	
TITLE (ENGLISH):	NOVEL THERAPEUTIC DELIVERY SYSTEMS	
TITLE (FRENCH):	NOUVEAU SYSTEME D'ADMINISTRATION DE PRODUITS THERAPEUTIQUES	

INVENTOR(S): UNGER, Evan, C.;
FRITZ, Thomas, A.;
MATSUNAGA, Terry;
RAMASWAMI, VaradaRajan;
YELLOWHAIR, David;
WU, Guanli

PATENT ASSIGNEE(S): UNGER, Evan, C.;
FRITZ, Thomas, A.;
MATSUNAGA, Terry;
RAMASWAMI, VaradaRajan;
YELLOWHAIR, David;
WU, Guanli

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9428874	A1	19941222

DESIGNATED STATES
W: AU CA CN JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL
PT SE

APPLICATION INFO.: WO 1994-US5633 A 19940519
PRIORITY INFO.: US 1993-8/076,250 19930611
US 1993-8/159,674 19931130
US 1993-8/159,687 19931130
US 1993-8/160,232 19931130

L18 ANSWER 10 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ACCESSION NUMBER: 1994028873 PCTFULL ED 20020513
TITLE (ENGLISH): NOVEL THERAPEUTIC DRUG DELIVERY SYSTEMS
TITLE (FRENCH): NOUVEAUX SYSTEMES D'ADMINISTRATION DE MEDICAMENTS
INVENTOR(S): UNGER, Evan, C.;
FRITZ, Thomas, A.;
MATSUNAGA, Terry;
RAMASWAMI, VaradaRajan;
YELLOWHAIR, David;
WU, Guanli

PATENT ASSIGNEE(S): UNGER, Evan, C.;
FRITZ, Thomas, A.;
MATSUNAGA, Terry;
RAMASWAMI, VaradaRajan;
YELLOWHAIR, David;
WU, Guanli

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9428873	A1	19941222

DESIGNATED STATES
W: AU CA CN JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL
PT SE

APPLICATION INFO.: WO 1994-US5620 A 19940512
PRIORITY INFO.: US 1993-8/076,250 19930611

=>.d kwic 10

L18 ANSWER 10 OF 11 PCTFULL COPYRIGHT 2005 Univentio on STN
ABEN Therapeutic drug delivery sytems comprising gas-filled
microspheres comprising a therapeutic
are described. Methods for employing such **microspheres** in
therapeutic drug delivery applications are

also provided. Drug delivery systems comprising gas-filled liposomes having encapsulated therein a drug are. . .

ABFR Systemes d'administration de medicaments au moyen de **microspheres** remplies d'un gaz a effet therapeutique, et methodes d'utilisation associees. Sont preconises des systemes d'administration a base de liposomes remplis. . .

DETD . . . deliver genetic material to 5 living cells. These mechanisms include techniques such as calcium phosphate precipitation and electroporation, and carriers such as cationic **polymers** and aqueous-filled liposomes. These methods have all been relatively ineffective in vivo and only of limited use for cell culture transfection. None of. . .

such as ganglioside GM1 and GM2; glucolipids; sulfatides; glycosphingolipids;

- 14 -

phosphatidic acid; palmitic acid; stearic acid; arachidonic acid; oleic acid; lipids bearing **polymers** such as polyethyleneglycol, chitin, hyaluronic acid or polyvinylpyrrolidone; lipids bearing sulfonated mono-, di-, 5 oligo- or polysaccharides; cholesterol, cholesterol sulfate and cholesterol hemisuccinate; tocopherol. . .

microsphere. Preferably, this non-cationic lipid is dipalmitoylphosphatidylcholine,

- 15 -

dipalmitoylphosphatidylethanolamine or dioleoylphosphatidylethanolamine. In lieu of cationic lipids as described above, lipids bearing cationic **polymers** such as polylysine or polyarginine may also be used to construct the microspheres 5 and afford binding of a negatively charged therapeutic,. . .

to

carbohydrates and their phosphorylated and sulfonated derivatives; polyethers, preferably with molecular weight ranges between 400 and 8000; di- and trihydroxy alkanes and their **polymers**, preferably with molecular weight ranges between 800 and 8000. Emulsifying and/or solubilizing agents may also be used in conjunction with lipids or. . .

methicillin, nafcillin, oxacillin, penicillin G, penicillin V, ticarcillin rifampin and tetracycline; antiinflammatories such as diflunisal, ibuprofen, indomethacin, meclofenamate, mefenamic acid, naproxen, oxyphenbutazone, phenylbutazone, piroxicam, **sulindac**, tolmetin, aspirin and salicylates; 20 antiprotozoans such as chloroquine, hydroxychloroquine, metronidazole, quinine and meglumine antimonate; antirheumatics such as penicillamine; narcotics such as paregoric; opiates. . .

DNA and analogs thereof, such as 20 phosphorothioate and phosphorodithioate oligodeoxynucleotides. Additionally, the genetic material may be combined, for example, with proteins or other **polymers**.

form the microspheres include, for example, proteins such as albumin, synthetic peptides such as polyglutamic acid, and linear and branched oligomers and **polymers** of

- 25 -

galactose, glucose and other hexosaccharides and **polymers** derived from phosphorylated and sulfonated pentose and hexose sugars and sugar alcohols. Carbohydrate **polymers** such as alginic acid, dextran, starch and HETA starch may also be used. Other natural **polymers**, such as hyaluronic acid, may be utilized. Synthetic **polymers** such as polyethyleneglycol, polyvinylpyrrolidone, polylactide, polyethyleneimines (linear and branched), polyionenes or polyiminocarboxylates may also be employed.

=> d his

(FILE 'HOME' ENTERED AT 08:21:20 ON 15 DEC 2005)

FILE 'PCTFULL' ENTERED AT 08:21:30 ON 15 DEC 2005

L1	15203 S MICROSPHER?
L2	343 S L1/TI
L3	990 S L1/AB
L4	1026 S L2 OR L3
L5	6164 S POLYANHYDRIDE
L6	2826 S SULINDAC
L7	16 S L6 AND L4
L8	3 S L7 AND L5
L9	16 S L7 AND POLYMER
L10	12 S L7 NOT PY>2002
L11	90719 S CANCER? OR TUMOR? OR CANCER?
L12	12 S L11 AND L10
L13	89307 S POLYMERIC
L14	89310 S L13 OR L9
L15	189307 S POLYMER
L16	208045 S L15 OR L13
L17	16 S L16 AND L7
L18	11 S L17 NOT PY>2001

ACCESSION NUMBER: 2002:259707 CAPLUS
DOCUMENT NUMBER: 136:379639
TITLE: Primary chemoprevention of familial adenomatous polyposis with sulindac
AUTHOR(S): Giardiello, Francis M.; Yang, Vincent W.; Hyland, Linda M.; Krush, Anne J.; Petersen, Gloria M.; Trimbath, Jill D.; Piantadosi, Steven; Garrett, Elizabeth; Geiman, Deborah E.; Hubbard, Walter; Offerhaus, Johan A.; Hamilton, Stanley R.
CORPORATE SOURCE: Dep. Med., Johns Hopkins Univ. Sch. Med., Baltimore, MD, USA
SOURCE: New England Journal of Medicine (2002), 346(14), 1054-1059
CODEN: NEJMAG; ISSN: 0028-4793
PUBLISHER: Massachusetts Medical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background: Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of **colorectal** adenomas and, eventually, **colorectal** cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown. Methods: The authors conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25yr) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac **orally** twice a day or identical-appearing placebo tablets for 48 mo. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing **colorectal** mucosa. Results: After four years of treatment, the average rate of compliance exceeded 76 % in the sulindac group, and mucosal prostaglandin levels were lower in this group than in the placebo group. During the course of the study, adenomas developed in 9 of 21 subjects (43 %) in the sulindac group and 11 of 20 subjects in the placebo group (55 %) ($P = 0.54$). There were no significant differences in the mean number ($P = 0.69$) or size ($P = 0.17$) of polyps between the groups. Sulindac did not slow the development of adenomas, according to an evaluation involving linear longitudinal methods. Conclusions: Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Background: Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of **colorectal** adenomas and, eventually, **colorectal** cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown. Methods: The authors conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25 yr) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac **orally** twice a day or identical-appearing placebo tablets for 48 mo. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing **colorectal** mucosa. Results: After four years of treatment, the average rate of compliance exceeded 76 % in the sulindac group, and mucosal prostaglandin levels were lower in this group than in the placebo group. During the course of the study, adenomas developed in 9 of 21 subjects (43 %) in the sulindac group and 11 of 20 subjects in the placebo group (55 %) ($P = 0.54$). There were no significant differences in the mean number ($P = 0.69$) or size ($P = 0.17$) of

polyps between the groups. Sulindac did not slow the development of adenomas, according to an evaluation involving linear longitudinal methods. Conclusions: Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.

IT Prostaglandins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**colorectal** mucosa prostaglandin levels as measure of
sulindac local effect in humans with familial adenomatous polyposis)

IT Antitumor agents

(**colorectal**, adenoma; primary chemoprevention of familial
adenomatous polyposis with sulindac in humans)

IT Intestine, neoplasm

(**colorectal**, inhibitors, adenoma; primary chemoprevention of
familial adenomatous polyposis with sulindac in humans)

IT Intestine, neoplasm

(familial polyposis; primary chemoprevention of familial adenomatous
polyposis with sulindac in humans)

IT Intestine

(large, mucosa; **colorectal** mucosa prostaglandin levels as
measure of sulindac local effect in humans with familial adenomatous
polyposis)

IT 363-24-6, Prostaglandin E2 551-11-1, Prostaglandin F2 α
13367-85-6, Prostaglandin B2 41598-07-6, Prostaglandin D2 58962-34-8,
6-keto-Prostaglandin F1 α

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**colorectal** mucosa prostaglandin levels as measure of
sulindac local effect in humans with familial adenomatous polyposis)

IT 38194-50-2, Sulindac

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(primary chemoprevention of familial adenomatous **polyposis**
with sulindac in humans)

69/4799, 651

ACCESSION NUMBER: 2001035956 PCTFULL ED 20020820
TITLE (ENGLISH): USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC
CANCER
TITLE (FRENCH): UTILISATION DES AINS DANS LE TRAITEMENT DU
CANCER DU PANCREAS
INVENTOR(S): MARSHALL, Mark, Steven;
SWEENEY, Christopher, J.;
YIP-SCHNEIDER, Michelle, T.;
CROWELL, Pamela, L.
PATENT ASSIGNEE(S): ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC.;
MARSHALL, Mark, Steven;
SWEENEY, Christopher, J.;
YIP-SCHNEIDER, Michelle, T.;
CROWELL, Pamela, L.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001035956	A1	20010525

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US31410 A 20001115
PRIORITY INFO.: US 1999-60/165,543 19991115

L40 ANSWER 2 OF 2

ACCESSION NUMBER: PCTFULL COPYRIGHT 2005 Univentio on STN
1999049859 PCTFULL ED 20020515
TITLE (ENGLISH): DFMO AND SULINDAC COMBINATION IN **CANCER**
CHEMOPREVENTION
TITLE (FRENCH): COMBINAISON DE DFMO ET DE SULINDAC DANS LA
CHIMIOPREVENTION DU **CANCER**
INVENTOR(S): GERNER, Eugene, W.;
MEYSKENS, Frank, L., Jr.
PATENT ASSIGNEE(S): THE ARIZONA BOARD OF REGENTS on behalf of THE
UNIVERSITY OF ARIZONA;
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;
GERNER, Eugene, W.;
MEYSKENS, Frank, L., Jr.

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9949859	A1	19991007

DESIGNATED STATES
W:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD
TG

APPLICATION INFO.: WO 1999-US6693 A 19990326
PRIORITY INFO.: US 1998-60/079,850 19980328